In this episode, Samantha Strong, PharmD, BCACP, AAHIVP, CDCES, and Nimish Patel, PharmD, PhD, AAHIVP, cover the most impactful clinical studies presented at CROI 2024, including:New data on long-acting ART, including:The CARES study of LA CAB + RPV in a sub-Saharan African population using a public health approachThe IMPAACT 2017 MOCHA study evaluating switching to LA CAB + RPV in adolescents living with HIVThe ACTG A5359 LATITUDE study of LA CAB + RPV in people with adherence challenges to oral ARTUpdated data from San Francisco’s Ward 86 Clinic using LA CAB + RPV in people without viral suppression at baselineCase series of LA CAB (± RPV) + LEN for select people living with HIV unable to take oral ART and unable to use LA CAB + RPV aloneData on HIV and STI prevention, including:The impact of Doxy-PEP guideline implementation on STIs in men who have sex with men and transgender women in San FranciscoBIC/FTC/TAF for PEPOffering PrEP following PEPPresenters:Samantha Strong, PharmD, BCACP, AAHIVP, CDCESClinical Director of PharmacyNevada Health CentersLas Vegas, NevadaNimish Patel, PharmD, PhD, AAHIVPProfessor of Clinical PharmacySkaggs School of Pharmacy & Pharmaceutical SciencesUniversity of California, San DiegoLa Jolla, CaliforniaTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.See the full program here: https://bit.ly/49x0W6D Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related